Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research note published on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.

Cellectis Stock Performance

Shares of NASDAQ CLLS opened at $1.80 on Friday. Cellectis has a 1 year low of $0.96 and a 1 year high of $3.77. The firm has a market cap of $100.05 million, a P/E ratio of -1.48 and a beta of 3.09. The stock has a fifty day moving average price of $2.17 and a two-hundred day moving average price of $2.34. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.92 and a current ratio of 1.92.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.05. The business had revenue of $9.50 million during the quarter, compared to analyst estimates of $6.00 million. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. Research analysts forecast that Cellectis will post -0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Several hedge funds have recently made changes to their positions in CLLS. Long Focus Capital Management LLC boosted its holdings in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after buying an additional 130,000 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of Cellectis by 6.2% during the 1st quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company’s stock valued at $1,125,000 after acquiring an additional 24,906 shares during the last quarter. First Affirmative Financial Network bought a new stake in shares of Cellectis during the 3rd quarter worth $45,000. XTX Topco Ltd acquired a new position in shares of Cellectis in the 2nd quarter worth $29,000. Finally, Baillie Gifford & Co. raised its position in shares of Cellectis by 1.3% during the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock worth $2,192,000 after purchasing an additional 10,605 shares during the period. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.